Credit rating agency, India Ratings and Research (Ind-Ra) in its latest report has projected that the revenue of India’s pharmaceutical market (IPM) witnessed 3.3% yoy (year on year) decline during May 2022 on the back of a fall in the sales volumes in acute segment therapies namely anti-infectives, vitamins and respiratory products due to the higher base effect during May 2021 and an inventory correction in the channel.
According to the report, strong volume declines were observed in key therapies such as anti-infectives, vitamins, respiratory and pain/analgesics while derma, central nervous system (CNS) and gynaec therapy reported robust volume growth in May 2022.
The rating agency further highlighted that the IPM performance in May 2022 is better than the agency’s and industry’s expectation, given the high base of 48% yoy growth in May 2021 and expects a positive growth trajectory from June 2022. The revenue growth of 47.8% yoy in May 2021 was led by strong buying patterns impacted by the COVID-19 outbreak.
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: